This is an open-label PET/CT study to investigate the safety and clinical monitoring value of 18F-grazy-02 in patients with lymphoma or solid tumors receiving immunotherapy, including immune checkpoint inhibition and CAR-T cell therapy.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
30
18F-grazy-02 PET/CT: after intravenous injection of 2.96-3.7 MBq/kg body weight of quality-controlled 18F-grazy-02 , a Total-body PET/CT uEXPLORER scanner will be applied.
Peking University Cancer Hospital & Institute
Beijing, Beijing Municipality, China
RECRUITINGIncidence of 18F-grazy-02-emergent Adverse Events
Any adverse events following the administration of the radiotracer will be monitored.
Time frame: 1 year
Biodistribution of 18F-grazy-02 in participants
The distribution of 18F-grazy-02 in tumors and healthy tissues will be examined through PET/CT imaging.
Time frame: 1 year
Assessing 18F-grazy-02 PET for monitoring immunotherapy responses
Participants will be categorized into groups with high or low 18F-grazy-02 uptake in tumor lesions. Therapy efficacy of immunotherapy as assessed by RECIST 1.1 will be compared across these two groups.
Time frame: 3 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.